Evidence map›Paper›PMID 30379917›Full record

ArticlePloS one2018

Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients.

Brooke Rhead, Ina S Brorson, Tone Berge, Cameron Adams, Hong Quach, Stine Marit Moen, Pål Berg-Hansen, Elisabeth Gulowsen Celius, Dipen P Sangurdekar, Paola G Bronson and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. CD4Epigenetics · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Brooke RheadComputational Biology Graduate Group, University of California, Berkeley, Berkeley, CA, United States of America.ORCID 0000-0002-1839-4883
Ina S BrorsonInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0001-6691-9413
Tone BergeDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Cameron AdamsGenetic Epidemiology and Genomics Laboratory, Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States of America.
Hong QuachGenetic Epidemiology and Genomics Laboratory, Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States of America.
Stine Marit MoenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Pål Berg-HansenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Elisabeth Gulowsen CeliusDepartment of Neurology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-9127-6488
Dipen P SangurdekarTranslational & Integrative Analytics, Biogen, Inc., Cambridge, MA, United States of America.ORCID 0000-0001-9474-0808
Paola G BronsonStatistical Genetics & Genetic Epidemiology, Biogen, Inc., Cambridge, MA, United States of America.
Rodney A LeaInstitute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.
Sean BurnardCentre for Information Based Medicine, Hunter Medical Research Institute, Newcastle, Australia.ORCID 0000-0003-2149-3556
Vicki E MaltbyCentre for Information Based Medicine, Hunter Medical Research Institute, Newcastle, Australia.ORCID 0000-0002-3785-4742
Rodney J ScottCentre for Information Based Medicine, Hunter Medical Research Institute, Newcastle, Australia.ORCID 0000-0001-7724-3404
Jeannette Lechner-ScottCentre for Information Based Medicine, Hunter Medical Research Institute, Newcastle, Australia.
Hanne F HarboInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0002-6047-0122
Steffan D BosInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0002-2975-7520
Lisa F BarcellosComputational Biology Graduate Group, University of California, Berkeley, Berkeley, CA, United States of America.
Oslo University Hospital · NOUniversity of California, Berkeley · USBiogen (United States) · USHunter Medical Research Institute · AUJohn Hunter Hospital · AUQueensland University of Technology · AU

Funding

Novel Strategies to Identify GxE Contributions to MS PathogenesisR01ES017080 · NIEHS · UNIVERSITY OF CALIFORNIA BERKELEY · PI BARCELLOS, LISA F · 2011 to 2015
$3.0M
Establishing the Causal Role of Low Vitamin D in Multiple SclerosisF31NS096885 · NINDS · UNIVERSITY OF CALIFORNIA BERKELEY · PI RHEAD, BROOKE · 2016 to 2019
$125k
CIHRNIEHS NIH HHS R01 ES017080NINDS NIH HHS F31 NS096885
6 · The paper itself

Abstract

DNA methylation is an epigenetic mark that is influenced by environmental factors and is associated with changes to gene expression and phenotypes. It may link environmental exposures to disease etiology or indicate important gene pathways involved in disease pathogenesis. We identified genomic regions that are differentially methylated in T cells of patients with relapsing remitting multiple sclerosis (MS) compared to healthy controls. DNA methylation was assessed at 450,000 genomic sites in CD4+ and CD8+ T cells purified from peripheral blood of 94 women with MS and 94 healthy women, and differentially methylated regions were identified using bumphunter. Differential DNA methylation was observed near four loci: MOG/ZFP57, HLA-DRB1, NINJ2/LOC100049716, and SLFN12. Increased methylation of the first exon of the SLFN12 gene was observed in both T cell subtypes and remained present after restricting analyses to samples from patients who had never been on treatment or had been off treatment for more than 2.5 years. Genes near the regions of differential methylation in T cells were assessed for differential expression in whole blood samples from a separate population of 1,329 women with MS and 97 healthy women. Gene expression of HLA-DRB1, NINJ2, and SLFN12 was observed to be decreased in whole blood in MS patients compared to controls. We conclude that T cells from MS patients display regions of differential DNA methylation compared to controls, and corresponding gene expression differences are observed in whole blood. Two of the genes that showed both methylation and expression differences, NINJ2 and SLFN12, have not previously been implicated in MS. SLFN12 is a particularly compelling target of further research, as this gene is known to be down-regulated during T cell activation and up-regulated by type I interferons (IFNs), which are used to treat MS.

Indexed as

DNA MethylationAdultCarrier ProteinsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansMiddle AgedMultiple SclerosisCarrier ProteinsSLFN12L protein, human

Identifiers

PMID30379917
PMCPMC6209300
OpenAlexW2899099233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.